Loading…
Veterinary Management of Harderian Gland Tumors in Cancer Rainbow (crainbow) HER2-Positive Mice
A Cancer Rainbow mouse line that expresses 3 fluorescently labeled isoforms of the tumor-driver gene HER2 (HER2BOW) was developed recently for the study of tumorigenesis in the mammary gland. The expression of 1 of the 3 HER2 isoforms in HER2BOW mice is induced through the Cre/lox system. However, i...
Saved in:
| Published in: | Comparative medicine 2022-12, Vol.72 (6), p.403-409 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c462t-b86bc7d4bcc0e4005e9d8237a10eee4c64da605a1a1b9dfa7276ac5966f6aa1c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c462t-b86bc7d4bcc0e4005e9d8237a10eee4c64da605a1a1b9dfa7276ac5966f6aa1c3 |
| container_end_page | 409 |
| container_issue | 6 |
| container_start_page | 403 |
| container_title | Comparative medicine |
| container_volume | 72 |
| creator | Garner, Angela Ginzel, Joshua D Snyder, Joshua C Everitt, Jeffrey I Landon, Chelsea D |
| description | A Cancer Rainbow mouse line that expresses 3 fluorescently labeled isoforms of the tumor-driver gene HER2 (HER2BOW) was developed recently for the study of tumorigenesis in the mammary gland. The expression of 1 of the 3 HER2 isoforms in HER2BOW mice is induced through the Cre/lox
system. However, in addition to developing palpable mammary tumors, HER2BOW mice developed orbital tumors, specifically of the Harderian gland. Mice were euthanized, and histopathologic examination of the Harderian gland tumors was performed. Tumors were characterized by adenomatous hyperplasia
to multinodular adenomas of the Harderian gland. Fluorescent imaging of the Harderian gland tissue confirmed the expression of HER2 in the tumors. Here we discuss monitoring and palliative approaches to allow attainment of humane experimental endpoints of mammary tumor growth in this mouse
line. We describe a range of interventions, including close monitoring, topical palliative care, and surgical bilateral enucleation. Based on our data and previous reports in the literature, the overexpression of HER2 in Harderian gland tissue and subsequent tumor formation likely was driven
by MMTV-Cre expression in the Harderian gland. |
| doi_str_mv | 10.30802/AALAS-CM-22-000061 |
| format | article |
| fullrecord | <record><control><sourceid>pubtec_cross</sourceid><recordid>TN_cdi_crossref_primary_10_30802_AALAS_CM_22_000061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>aalas/cm/2022/00000072/00000006/art00006</ingid><sourcerecordid>aalas/cm/2022/00000072/00000006/art00006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-b86bc7d4bcc0e4005e9d8237a10eee4c64da605a1a1b9dfa7276ac5966f6aa1c3</originalsourceid><addsrcrecordid>eNpVUcFu1DAUtBCILoUvQEI-lkPg2Uns5IJYRaWLtCtQKYib9eI4i6vEbu2kqH9fa7OtwBePNPPGbzyEvGXwIYcK-Mf1erv-kTW7jPMM0hHsGVlxKeqsYvXv52TFyjwxFYcT8irGawBe18BfkpNcyKIooVoR9ctMJliH4Z7u0OHejMZN1Pd0g6FLDDp6MaDr6NU8-hCpdbRBp02gl2hd6__SMx0W9J5uzi959t1HO9k7Q3dWm9fkRY9DNG-O9yn5-eX8qtlk228XX5v1NtOF4FPWVqLVsitarcEUAKWpu4rnEhkYYwotig4FlMiQtXXXo0wxUZe1EL1AZDo_JZ8W35u5HU2nU4iAg7oJdkzRlEer_mec_aP2_k7VVbJikAzOjgbB384mTmq0UZshZTd-jopLmUsOspJJmi9SHXyMwfRPzzBQh2rUoRrV7BTnaqkmTb37d8OnmccukuDzIrBun5ZEde3n4NKnKcQBo9Kj4nD0A5CPAITCMB1A_gAnWZ_i</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2773720787</pqid></control><display><type>article</type><title>Veterinary Management of Harderian Gland Tumors in Cancer Rainbow (crainbow) HER2-Positive Mice</title><source>PMC (PubMed Central)</source><source>IngentaConnect Journals</source><creator>Garner, Angela ; Ginzel, Joshua D ; Snyder, Joshua C ; Everitt, Jeffrey I ; Landon, Chelsea D</creator><creatorcontrib>Garner, Angela ; Ginzel, Joshua D ; Snyder, Joshua C ; Everitt, Jeffrey I ; Landon, Chelsea D</creatorcontrib><description>A Cancer Rainbow mouse line that expresses 3 fluorescently labeled isoforms of the tumor-driver gene HER2 (HER2BOW) was developed recently for the study of tumorigenesis in the mammary gland. The expression of 1 of the 3 HER2 isoforms in HER2BOW mice is induced through the Cre/lox
system. However, in addition to developing palpable mammary tumors, HER2BOW mice developed orbital tumors, specifically of the Harderian gland. Mice were euthanized, and histopathologic examination of the Harderian gland tumors was performed. Tumors were characterized by adenomatous hyperplasia
to multinodular adenomas of the Harderian gland. Fluorescent imaging of the Harderian gland tissue confirmed the expression of HER2 in the tumors. Here we discuss monitoring and palliative approaches to allow attainment of humane experimental endpoints of mammary tumor growth in this mouse
line. We describe a range of interventions, including close monitoring, topical palliative care, and surgical bilateral enucleation. Based on our data and previous reports in the literature, the overexpression of HER2 in Harderian gland tissue and subsequent tumor formation likely was driven
by MMTV-Cre expression in the Harderian gland.</description><identifier>ISSN: 1532-0820</identifier><identifier>EISSN: 2769-819X</identifier><identifier>DOI: 10.30802/AALAS-CM-22-000061</identifier><identifier>PMID: 36744508</identifier><language>eng</language><publisher>United States: American Association for Laboratory Animal Science</publisher><subject>Animals ; Case Studies ; Harderian Gland - pathology ; Mammary Neoplasms, Animal - genetics ; Mammary Neoplasms, Animal - pathology ; Mice ; Mice, Transgenic</subject><ispartof>Comparative medicine, 2022-12, Vol.72 (6), p.403-409</ispartof><rights>American Association for Laboratory Animal Science 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-b86bc7d4bcc0e4005e9d8237a10eee4c64da605a1a1b9dfa7276ac5966f6aa1c3</citedby><cites>FETCH-LOGICAL-c462t-b86bc7d4bcc0e4005e9d8237a10eee4c64da605a1a1b9dfa7276ac5966f6aa1c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827610/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827610/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53728,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36744508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garner, Angela</creatorcontrib><creatorcontrib>Ginzel, Joshua D</creatorcontrib><creatorcontrib>Snyder, Joshua C</creatorcontrib><creatorcontrib>Everitt, Jeffrey I</creatorcontrib><creatorcontrib>Landon, Chelsea D</creatorcontrib><title>Veterinary Management of Harderian Gland Tumors in Cancer Rainbow (crainbow) HER2-Positive Mice</title><title>Comparative medicine</title><addtitle>Comp Med</addtitle><addtitle>Comp Med</addtitle><description>A Cancer Rainbow mouse line that expresses 3 fluorescently labeled isoforms of the tumor-driver gene HER2 (HER2BOW) was developed recently for the study of tumorigenesis in the mammary gland. The expression of 1 of the 3 HER2 isoforms in HER2BOW mice is induced through the Cre/lox
system. However, in addition to developing palpable mammary tumors, HER2BOW mice developed orbital tumors, specifically of the Harderian gland. Mice were euthanized, and histopathologic examination of the Harderian gland tumors was performed. Tumors were characterized by adenomatous hyperplasia
to multinodular adenomas of the Harderian gland. Fluorescent imaging of the Harderian gland tissue confirmed the expression of HER2 in the tumors. Here we discuss monitoring and palliative approaches to allow attainment of humane experimental endpoints of mammary tumor growth in this mouse
line. We describe a range of interventions, including close monitoring, topical palliative care, and surgical bilateral enucleation. Based on our data and previous reports in the literature, the overexpression of HER2 in Harderian gland tissue and subsequent tumor formation likely was driven
by MMTV-Cre expression in the Harderian gland.</description><subject>Animals</subject><subject>Case Studies</subject><subject>Harderian Gland - pathology</subject><subject>Mammary Neoplasms, Animal - genetics</subject><subject>Mammary Neoplasms, Animal - pathology</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><issn>1532-0820</issn><issn>2769-819X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVUcFu1DAUtBCILoUvQEI-lkPg2Uns5IJYRaWLtCtQKYib9eI4i6vEbu2kqH9fa7OtwBePNPPGbzyEvGXwIYcK-Mf1erv-kTW7jPMM0hHsGVlxKeqsYvXv52TFyjwxFYcT8irGawBe18BfkpNcyKIooVoR9ctMJliH4Z7u0OHejMZN1Pd0g6FLDDp6MaDr6NU8-hCpdbRBp02gl2hd6__SMx0W9J5uzi959t1HO9k7Q3dWm9fkRY9DNG-O9yn5-eX8qtlk228XX5v1NtOF4FPWVqLVsitarcEUAKWpu4rnEhkYYwotig4FlMiQtXXXo0wxUZe1EL1AZDo_JZ8W35u5HU2nU4iAg7oJdkzRlEer_mec_aP2_k7VVbJikAzOjgbB384mTmq0UZshZTd-jopLmUsOspJJmi9SHXyMwfRPzzBQh2rUoRrV7BTnaqkmTb37d8OnmccukuDzIrBun5ZEde3n4NKnKcQBo9Kj4nD0A5CPAITCMB1A_gAnWZ_i</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Garner, Angela</creator><creator>Ginzel, Joshua D</creator><creator>Snyder, Joshua C</creator><creator>Everitt, Jeffrey I</creator><creator>Landon, Chelsea D</creator><general>American Association for Laboratory Animal Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221201</creationdate><title>Veterinary Management of Harderian Gland Tumors in Cancer Rainbow (crainbow) HER2-Positive Mice</title><author>Garner, Angela ; Ginzel, Joshua D ; Snyder, Joshua C ; Everitt, Jeffrey I ; Landon, Chelsea D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-b86bc7d4bcc0e4005e9d8237a10eee4c64da605a1a1b9dfa7276ac5966f6aa1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Case Studies</topic><topic>Harderian Gland - pathology</topic><topic>Mammary Neoplasms, Animal - genetics</topic><topic>Mammary Neoplasms, Animal - pathology</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garner, Angela</creatorcontrib><creatorcontrib>Ginzel, Joshua D</creatorcontrib><creatorcontrib>Snyder, Joshua C</creatorcontrib><creatorcontrib>Everitt, Jeffrey I</creatorcontrib><creatorcontrib>Landon, Chelsea D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Comparative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garner, Angela</au><au>Ginzel, Joshua D</au><au>Snyder, Joshua C</au><au>Everitt, Jeffrey I</au><au>Landon, Chelsea D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Veterinary Management of Harderian Gland Tumors in Cancer Rainbow (crainbow) HER2-Positive Mice</atitle><jtitle>Comparative medicine</jtitle><stitle>Comp Med</stitle><addtitle>Comp Med</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>72</volume><issue>6</issue><spage>403</spage><epage>409</epage><pages>403-409</pages><issn>1532-0820</issn><eissn>2769-819X</eissn><abstract>A Cancer Rainbow mouse line that expresses 3 fluorescently labeled isoforms of the tumor-driver gene HER2 (HER2BOW) was developed recently for the study of tumorigenesis in the mammary gland. The expression of 1 of the 3 HER2 isoforms in HER2BOW mice is induced through the Cre/lox
system. However, in addition to developing palpable mammary tumors, HER2BOW mice developed orbital tumors, specifically of the Harderian gland. Mice were euthanized, and histopathologic examination of the Harderian gland tumors was performed. Tumors were characterized by adenomatous hyperplasia
to multinodular adenomas of the Harderian gland. Fluorescent imaging of the Harderian gland tissue confirmed the expression of HER2 in the tumors. Here we discuss monitoring and palliative approaches to allow attainment of humane experimental endpoints of mammary tumor growth in this mouse
line. We describe a range of interventions, including close monitoring, topical palliative care, and surgical bilateral enucleation. Based on our data and previous reports in the literature, the overexpression of HER2 in Harderian gland tissue and subsequent tumor formation likely was driven
by MMTV-Cre expression in the Harderian gland.</abstract><cop>United States</cop><pub>American Association for Laboratory Animal Science</pub><pmid>36744508</pmid><doi>10.30802/AALAS-CM-22-000061</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1532-0820 |
| ispartof | Comparative medicine, 2022-12, Vol.72 (6), p.403-409 |
| issn | 1532-0820 2769-819X |
| language | eng |
| recordid | cdi_crossref_primary_10_30802_AALAS_CM_22_000061 |
| source | PMC (PubMed Central); IngentaConnect Journals |
| subjects | Animals Case Studies Harderian Gland - pathology Mammary Neoplasms, Animal - genetics Mammary Neoplasms, Animal - pathology Mice Mice, Transgenic |
| title | Veterinary Management of Harderian Gland Tumors in Cancer Rainbow (crainbow) HER2-Positive Mice |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T21%3A59%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubtec_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Veterinary%20Management%20of%20Harderian%20Gland%20Tumors%20in%20Cancer%20Rainbow%20(crainbow)%20HER2-Positive%20Mice&rft.jtitle=Comparative%20medicine&rft.au=Garner,%20Angela&rft.date=2022-12-01&rft.volume=72&rft.issue=6&rft.spage=403&rft.epage=409&rft.pages=403-409&rft.issn=1532-0820&rft.eissn=2769-819X&rft_id=info:doi/10.30802/AALAS-CM-22-000061&rft_dat=%3Cpubtec_cross%3Eaalas/cm/2022/00000072/00000006/art00006%3C/pubtec_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-b86bc7d4bcc0e4005e9d8237a10eee4c64da605a1a1b9dfa7276ac5966f6aa1c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2773720787&rft_id=info:pmid/36744508&rft_ingid=aalas/cm/2022/00000072/00000006/art00006&rfr_iscdi=true |